Patent Score Card: Kyle Bass Gets 17 IPR Reviews Granted, 14 Denied
This article was originally published in The Pink Sheet Daily
Bass wins review of four Acorda patents based on SEC registration filing; Patent Trial and Appeal Board declines to institute inter partes review of Enbrel patent and Insys' Subsys patents but okays trial on Juxtapid patents.
You may also be interested in...
Patent Trial and Appeal Board upheld validity of four Acorda patents; district court judge to issue decision on five patents. Victory would block generic competition until 2025.
Patent board has instituted 19 other inter partes review proceedings sought by the hedge fund manager and declined to institute 14.
Existing emergency use authorizations to remain in effect and FDA may continue to issue new ones. Pfizer and Merck are moving to transition Paxlovid and Lagevrio to full approval as FDA allows prescribing without a positive COVID test first.